CareLit · DOI-Nachweis · Klinische Pädiatrie
Phase 2, open-label study of pembrolizumab in children and young adults with newly diagnosed classical hodgkin lymphoma (cHL) with slow early response (SER) to frontline chemotherapy: KEYNOTE-667
DOI 10.1055/s-0040-1701823
Bibliografische Angaben
Nachweis in CareLit
Autor:innenKM Kelly, FG Keller, R Ramchandren, A Nahar, L Giulino-Roth
ZeitschriftKlinische Pädiatrie
Ausgabe02/2020
Jahrgang / SeitenJg. 232
Kernaussage aus der Literatur
Abstract-Vorschau
Phase 2, open-label study of pembrolizumab in children and young adults with newly diagnosed classical hodgkin lymphoma (cHL) with slow early response (SER) to frontline chemotherapy: KEYNOTE-667
Zitieren
Zitierempfehlung
KM Kelly, FG Keller, R Ramchandren, A Nahar, L Giulino-Roth (2020) Phase 2, open-label study of pembrolizumab in children and young adults with newly diagnosed classical hodgkin lymphoma (cHL) with slow early response (SER) to frontline chemotherapy: KEYNOTE-667. Klinische Pädiatrie, 232 (02). https://doi.org/10.1055/s-0040-1701823
Mit CareLit weiterarbeiten